Adiponectin levels are elevated in patients with pulmonary arterial hypertension

Clinical Cardiology

Volumn 37, Issue 1, 2014, Pages 21-25

  Santos, Mário ^a,b   Reis, Abílio ^c   Gonçalves, Fabienne ^c   Ferreira Pinto, Manuel J ^a   Cabral, Sofia ^b   Torres, Severo ^b   Leite Moreira, Adelino F ^a   Henriques Coelho, Tiago ^a  

^a Department of Physiology and Cardiothoracic Surgery ^*  (United States)

^b University of Porto   (Portugal)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHODIESTERASE INHIBITOR; RESISTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FUNCTIONAL STATUS; HEART INDEX; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EXERCISE TEST; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MIDDLE AGED; UP-REGULATION; YOUNG ADULT;

EID: 84892596784     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22210     Document Type: Article

References (31)

1. Lourenco AP, Fontoura D, Henriques-Coelho T, et al. Current pathophysiological concepts and management of pulmonary hypertension. Int J Cardiol. 2012; 155: 350-361.
2. Archer SL, Weir EK, Wilkins MR,. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation. 2010; 121: 2045-2066.
3. Okamoto Y, Kihara S, Funahashi T, et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond). 2006; 110: 267-278.
4. Tilg H, Moschen AR,. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6: 772-783.
5. Summer R, Fiack CA, Ikeda Y, et al. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol. 2009; 297: L432-L438.
6. Krenning G, Moonen JR, Harmsen MC,. Pleiotropism of adiponectin: inflammation, neovascularization, and fibrosis. Circ Res. 2009; 104: 1029-1031.
7. Liao Y, Takashima S, Maeda N, et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res. 2005; 67: 705-713.
8. Hansmann G, Wagner RA, Schellong S, et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007; 115: 1275-1284.
9. Medoff BD, Okamoto Y, Leyton P, et al. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol. 2009; 41: 397-406.
10. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005; 112: 1756-1762.
11. Van Berendoncks AM, Garnier A, Ventura-Clapier R, et al. Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure [published online ahead of print October 23, 2012]. Heart Fail Rev. doi:10.1007/s10741-012-9349-4.
12. Katagiri H, Yamada T, Oka Y,. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res. 2007; 101: 27-39.
13. Oda A, Taniguchi T, Yokoyama M,. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci. 2001; 47: 141-150.
14. Huertas A, Tu L, Gambaryan N, et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J. 2012; 40: 895-904.
15. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003; 108: 736-740.
16. Yamawaki H., Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011; 34: 307-310.
17. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30: 2493-2537.
18. Rickham PP,. Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J. 1964; 2: 177.
19. Hemnes AR, Forfia PR, Champion HC,. Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography. Int J Clin Pract Suppl. 2009;(162): 4-19.
20. Antuna-Puente B, Disse E, Rabasa-Lhoret R, et al. How can we measure insulin sensitivity/resistance? Diabetes Metab. 2011; 37: 179-188.
21. Thierer J, Acosta A, Vainstein N, et al. Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study). Am J Cardiol. 2010; 105: 977-983.
22. Khan RS, Kato TS, Chokshi A, et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail. 2012; 5: 340-348.
23. Bogaard HJ, Abe K, Vonk Noordegraaf A, et al. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009; 135: 794-804.
24. Biolo A, Shibata R, Ouchi N, et al. Determinants of adiponectin levels in patients with chronic systolic heart failure. Am J Cardiol. 2010; 105: 1147-1152.
25. Birkenfeld AL, Boschmann M, Engeli S, et al. Atrial natriuretic peptide and adiponectin interactions in man. PLoS One. 2012; 7: e43238.
26. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009; 53: 2070-2077.
27. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005; 46: 1019-1026.
28. Pugh ME, Robbins IM, Rice TW, et al. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant. 2011; 30: 904-911.
29. Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009; 33: 318-324.
30. Quarck R, Nawrot T, Meyns B, et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 53: 1211-1218.
31. Salamone LM, Fuerst T, Visser M, et al. Measurement of fat mass using DEXA: a validation study in elderly adults. J Appl Physiol. 2000; 89: 345-352.